Skip to content

Study · Non-randomized trial · n = 12 · 2005

7 results

The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.

Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV

The American journal of gastroenterology1 Apr 2005Cited by 61 (Europe PMC)

PMID15784036 (opens in a new tab)DOI10.1111/j.1572-0241.2005.40899.x (opens in a new tab)PepBankPUB-15784036
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In nonazotemic cirrhotic patients with ascites, octreotide alone did not improve systemic hemodynamics.

    In plain wordsIn cirrhotic patients with ascites, octreotide alone did not improve circulation compared with baseline.

    Peptide
    Octreotide
    Outcome
    Direction not reportedSystemic hemodynamics
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide did not improve systemic hemodynamics
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).
  2. 02HumanNon-randomized trialEfficacy outcome

    In nonazotemic cirrhotic patients with ascites, octreotide alone decreased renal vascular resistance from baseline.

    In plain wordsIn cirrhotic patients with ascites, octreotide alone reduced kidney vascular resistance from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseRenal vascular resistance
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide caused a decrease in renal vascular resistance (RVR) and increased renal blood flow (RBF) but significantly reduced glomerular filtration rate.
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).
  3. 03HumanNon-randomized trialEfficacy outcome

    In nonazotemic cirrhotic patients with ascites, octreotide alone increased renal blood flow from baseline.

    In plain wordsIn cirrhotic patients with ascites, octreotide alone increased kidney blood flow from baseline.

    Peptide
    Octreotide
    Outcome
    IncreaseRenal blood flow
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide caused a decrease in renal vascular resistance (RVR) and increased renal blood flow (RBF) but significantly reduced glomerular filtration rate.
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).
  4. 04HumanNon-randomized trialEfficacy outcome

    In nonazotemic cirrhotic patients with ascites, octreotide alone significantly reduced glomerular filtration rate from baseline.

    In plain wordsIn cirrhotic patients with ascites, octreotide alone reduced kidney filtration from baseline.

    Peptide
    Octreotide
    Outcome
    DecreaseGlomerular filtration rate
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide caused a decrease in renal vascular resistance (RVR) and increased renal blood flow (RBF) but significantly reduced glomerular filtration rate.
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).
  5. 05HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, plasma active renin fell significantly from baseline in both groups, including octreotide alone.

    In plain wordsIn cirrhotic patients, active renin fell from baseline in both groups, including octreotide alone.

    Peptide
    Octreotide
    Outcome
    DecreaseActive renin
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The plasma values of active renin, aldosterone, and glucagon were significantly reduced in either group.
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).
  6. 06HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, plasma aldosterone fell significantly from baseline in both groups, including octreotide alone.

    In plain wordsIn cirrhotic patients, aldosterone fell from baseline in both groups, including octreotide alone.

    Peptide
    Octreotide
    Outcome
    DecreaseAldosterone
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The plasma values of active renin, aldosterone, and glucagon were significantly reduced in either group.
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).
  7. 07HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, plasma glucagon fell significantly from baseline in both groups, including octreotide alone.

    In plain wordsIn cirrhotic patients, glucagon fell from baseline in both groups, including octreotide alone.

    Peptide
    Octreotide
    Outcome
    DecreaseGlucagon
    Study

    n = 12

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 mug twice daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The plasma values of active renin, aldosterone, and glucagon were significantly reduced in either group.
    1 context sentence
    Summary · context
    Twenty-five patients were studied at baseline and 11 days after administration of subcutaneous octreotide 300 mug, b.i.d. alone (n = 12) or together with oral midodrine 7.5 mg, t.i.d. (n = 13).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.